Gilead Sciences GILD
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Gilead Sciences (GILD) Business Model and Operations Summary
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Key Insights
Gilead Sciences (GILD) Core Market Data and Business Metrics
Latest Closing Price
$111.28Market Cap
$138.30 BillionPrice-Earnings Ratio
292.84Total Outstanding Shares
1.25 Billion SharesTotal Employees
17,600Dividend
$0.79 Per Share QuarterlyIPO Date
January 22, 1992SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
333 Lakeside Dr, Foster City, CA, 94404
Historical Stock Splits
If you bought 1 share of GILD before September 7, 2004, you'd have 8 shares today.
| Execution Date | Split Amount |
|---|---|
| January 28, 2013 | 2-for-1 |
| June 25, 2007 | 2-for-1 |
| September 7, 2004 | 2-for-1 |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-3.45 Billion |
| Net Cash Flow | $3.91 Billion |
| Exchange Gains/Losses | $-40 Million |
| Net Cash Flow From Operating Activities | $10.83 Billion |
| Net Cash Flow From Operating Activities, Continuing | $10.83 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-3.45 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $480 Million |
| Net Income/Loss | $480 Million |
| Income/Loss From Continuing Operations After Tax | $479 Million |
| Diluted Average Shares | $1.25 Billion |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Basic Average Shares | $1.25 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $584 Million |
| Comprehensive Income/Loss Attributable To Parent | $584 Million |
| Other Comprehensive Income/Loss | $104 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Inventory | $1.71 Billion |
| Long-term Debt | $26.71 Billion |
| Accounts Payable | $833 Million |
| Other Non-current Liabilities | $1.03 Billion |
| Assets | $58.99 Billion |
| Current Assets | $19.17 Billion |
Historical Dividends
Current dividend: $0.79 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Feb 11, 2025 | Mar 28, 2025 | Mar 14, 2025 | $0.79 | Quarterly |
| Nov 6, 2024 | Dec 30, 2024 | Dec 13, 2024 | $0.77 | Quarterly |
| Aug 8, 2024 | Sep 27, 2024 | Sep 13, 2024 | $0.77 | Quarterly |
| Apr 25, 2024 | Jun 27, 2024 | Jun 14, 2024 | $0.77 | Quarterly |
| Feb 1, 2024 | Mar 28, 2024 | Mar 15, 2024 | $0.77 | Quarterly |
| Nov 7, 2023 | Dec 28, 2023 | Dec 15, 2023 | $0.75 | Quarterly |